Given its involvement in tumour development and progression, the phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway has emerged as a promising therapeutic target in GBM. This evidence concerns the gene AKT1 and glioblastoma.